FCF Fox Corporate Finance | FCF Healthcare & Life Sciences Healthcare & Life Sciences Venture Capital Monitor – Europe

December 2023



Antibody



FCF HEALTHCARE & LIFE SCIENCES OVERVIEW




Overview





Our capital markets research feeds our proprietary investor database





The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe is a monthly published overview focusing on the venture capital financing environment in the Biotech. Pharmaceutical. MedTech and HealthTech segments, and can be used as a quick reference for investors, corporates and professionals

More advanced, detailed and / or customized reports are available upon request

FCF Healthcare & Life Sciences Venture Capital Monitor - Europe

is a monthly published overview of Biotech, Pharmaceutical, MedTech and HealthTech companies, displaying venture capital financing trends in the European healthcare & life science industry

Scope

The selection of companies is based on the following criteria:

- Focus on transactions with European headquartered healthcare & life science companies and available deal volume
- Companies operating in the Biotech, Pharmaceutical, MedTech, HealthTech, Services or other life science related sectors
- The Biotech sector is further divided into the following therapy areas / indications: Cardiovascular, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health, Metabolic Disorders, Mouth and Dental Disorders, Musculoskeletal, Non Malignant Disorders, Nutritional Disorders, Oncology, Ophthalmology, Respiratory, Toxicology, Women's Health

To recommend colleagues or fellow investors to be added to the mailing list, kindly send an email with the respective contact information

Recipients

The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe targets the following recipients:

- Corporates / ExecutivesInstitutional investors
- Venture capital investorsFamily Offices / High-
- Private equity investors
- Family Offices / Hig net-worth individuals
- Advisors

Availability

The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe is available on FCF's website at "https://www-fcf-de/de/life-sciences/"

Data

All input data is provided by Pitchbook and is not independently verified by FCF- Ratio and multiple calculations are driven based on the input data available- For additional information and disclaimer, please refer to the last page

If you have questions, comments or ideas, please do not hesitate to contact us




EUROPEAN VENTURE CAPITAL TRANSACTIONS IN HEALTHCARE & LIFE SCIENCES

DECEMBER 2023

European Venture Capital Transactions in Healthcare & Life Sciences

December 2023




Source: PitchBook as of 10-01-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded

C F European Venture Capital Transactions in Healthcare & Life Sciences

December 2023



Source: PitchBook as of 10-01-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded

European Venture Capital Transactions in Healthcare & Life Sciences \mathbf{F}^{-}

December 2023


FINANCING SPECIALIST

Overview (YTD)	# Date Co	ompany HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Volume Series (EURm		
Cumulative Financing Volume (EURm) 12,000 9,591 10,000 9,591 8,000 8,949 6,000 8,949	17 14/12/2023 De	eontics GBR	HealthTech	Healthcare Management Platform / On market	Developer of a clinical pathway system designed to guide the clinical team and improve healthcare outcomes with patient safety.	- 3	8	The company raised GBP 2.42 million of venture funding on December 14, 2023, putting the company's pre-money valuation at GBP 20.01 million.
4,000 2,000 0 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec <i>Financing Volume (December 2023): EUR 311m</i>	18 14/12/2023 Mii	iiskin DNK	HealthTech	Dermatology / On market	Developer of mole tracking application focused on detecting melanoma at an early stage.	- <1	2	The company raised DKK 2.6 million of venture funding on December 14, 2023.
Subsectors Indications ¹		BR Life GBR ciences GBR	Healthcare Services	Others / On market	Operator of a life science contract research organization intended to guide pharmaceutical companies to real opportunities.	, - <1	< 1	The company received \$120,000 in funding on December 14, 2023, putting the company's pre-money valuation at \$313,333. Out of the total funds \$100,000 was raised in the form of convertible debt.
HealthTech - 19% 8,949 m 42% Biolech / Pharma 42% Biolech / Pharma 45% 3,740 m 11% Contral Nervous System Metabolic Diphthalmology Dipotential System Metabolic	20 13/12/2023 Ae	esyra CHE	MedTech	Sleep Disorder / Undisclosed	Developer of medical devices designed for the care of people with sleep disorders.	ı - 3	3	The company raised CHF 2.63 million of venture funding on December 13, 2023, putting the company's pre-money valuation at an estimated CHF 5.78 million. The funds will be used to support the development and commercialization of Aesyra's AesyBite® line of products for accurate monitoring and treatment of sleep bruxism and sleep apnea.
Top Company Origins Top Investor Origins		eya DNK osciences	Biotech / Pharma	Women's Health / Undisclosed	Developer of microbial immunotherapies intended to address substantial unmet needs across a range of indications.	A 35	35	The company raised \$38 million of Series A venture funding on December 12, 2023. The funds will be used to advance clinical development of its lead drug candidate.
EUR 40% 8,949m 7% 15% 11% 15%	22 12/12/2023 La:	uza Medical CHE	MedTech	Cardiovascular / Undisclosed	Operator of a medical device development company intended to provide Al-powered robotically- assisted imaging for cardiovascular interventions.	A 33	36	The company raised \$36 million of Series A venture funding on December 12, 2023. The funds will be used to accelerate product development and further expand the team.
Top 5 Deals Deal Top 5 Investors # Company HQ Volume Series 1 YgEia3 R 683 E 2 Apollo Threapeutics 208 C 2 Jeito 1 177 13	23 12/12/2023 I-V	/irtual FRA	MedTech	Monitoring Device / Undisclosed	Developer of cognitive stimulation software and a device for measuring cardiac activity designed to specialize in the processing of images and data for everyday health and well-being.	- 3	6	The company raised EUR 3 million of venture funding on December 12, 2023. The funds will be used for commercial expansion in Europe and the continued development of its camera-based blood pressure measurement technology.
Therapeutics Image: Constraint of the		lendra GBR nerapeutics	Biotech / Pharma	Oncology / Pre-clinic	Developer of therapeutics designed to build on new insights into dendritic cell biology.	- 3	50	The company raised \$3.05 million of venture funding on December 12, 2023, putting the company's pre-money valuation at \$1.66 million.

Source: PitchBook as of 10-01-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


European Venture Capital Transactions in Healthcare & Life Sciences December 2023



Source: PitchBook as of 10-01-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded

European Venture Capital Transactions in Healthcare & Life Sciences



	1	# Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)) Deal Synopsis
		33 05/12/2023	Liftya	ITA	MedTech	Orthopedics / Undisclosed	Developer of a specialized shoulder assist device designed to provide stability with motion, whilst reducing pain to patients, who suffer from brain stroke or brachial plexus injuries.	-	2	2	The company raised EUR 1.5 million of venture funding on December 5, 2023.
		34 04/12/2023	SOM Biotech	ESP	Biotech / Pharma	Central Nervous System / Phase II	Developer of drugs designed for the treatment of rare and critical diseases.	В	17	42	The company raised EUR 17 million of Series B venture funding on December 4, 2023. The transaction was supported by EUR 7.5 million of debt financing. The funds will be used for the development of several R&D programs.
ogy		35 03/12/2023	Beyondbmi	IRL	HealthTech	Weight Management / On market	Operator of a health tech platform intended to specialize in weight management.	-	1	2	The company raised EUR 1 million of angel funding on December 3, 2023.
al Nervous lystem c s		36 01/12/2023	Mytos	GBR	Biotech / Pharma	Cell Manufacturing Platform / On market	Developer of a fully automated cell manufacturing platform designed to automate human cell production for pharma and biotech businesses.	A	18	26	The company raised \$19 million through Series A venture funding on December 1, 2023.

Source: PitchBook as of 10-01-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded

Contact Details & Disclaimer



FCF Fox Corporate Finance GmbH

Maximilianstrasse 12-14 • 80539 Munich • Germany Telephone +49 (89) 206 0409-0 • Facsimile +49 (89) 206 0409-299 info@fcf.de • www.fcf.de

Arno Fuchs Chief Executive Officer

P: +49 (89) 206 0409-100 M: +49 (172) 863 6777 arno.fuchs@fcf.de

> Johannes Link Associate

P: +49 (89) 206 0409-150 M: +49 (172) 839 5746 johannes.link@fcf.de

Mathias Klozenbuecher Managing Director

P: +49 (89) 2060 409-123

M: +49 (174) 301 1846 mathias.klozenbuecher@fcf.de

Marco Vollnhals Intern P: +49 (89) 206 0409-127 marco.vollnhals@fcf.de

DISCLAIMER

This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or may be relied upon in connection with any contract or commitment whatsoever. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither FCF nor any of its officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. By accepting this document you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. This document contains certain forward-looking statements, including assumptions, opinions and views cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. FCF does not guarantee that the figures, assumptions and calculations underlying such historical and forward looking statements are free from errors nor does FCF accept any responsibility for the future accuracy of the opinions expressed in this document or the actual occurrence of the forecasted developments.

© FCF Fox Corporate Finance GmbH 2024



THE FINANCING SPECIALIST